The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well, Regeneron Pharmaceuticals and Sanofi ...

Patients with chronic rhinosinusitis (CRS) with severe radiographic disease were more likely to report incidence of nasal polyps and be managed by endoscopic sinus surgery, but did not show greater ...

Patients with chronic rhinosinusitis with nasal polyps who had elevated serum amyloid A (SAA) levels were more likely to achieve disease-controlled status vs those with low SAA levels after endoscopic ...

For the millions of people living with nasal polyps, getting the right diagnosis and accessing effective treatment can take years. Today, on ...

A study of the nasal microbiome helped researchers predict recurrent polyps in chronic rhinosinusitis patients with more than 90% accuracy, based on data from 85 individuals. Chronic rhinosinusitis ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

Please provide your email address to receive an email when new articles are posted on . Mepolizumab reduced polyp size and nasal obstructions in patients with chronic rhinosinusitis with nasal polyps ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Diagnosing nasal polyps can be a long, challenging process. More than half of people who have them say it took over a year since developing symptoms to receive a diagnosis. Even after you’ve spoken to ...

THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the ...

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (AZN) and Amgen’s TEZSPIRE® (tezepelumab ...

CFTR modulators, especially triple therapy, significantly improve sinonasal inflammation and nasal polyp size in patients with cystic fibrosis.